• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinicopathological significance of TIGIT and soluble CD155 in breast cancer

Research Project

Project/Area Number 17K10533
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General surgery
Research InstitutionUniversity of Tsukuba

Principal Investigator

Iguchi Akiko  筑波大学, 医学医療系, 講師 (50575644)

Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
KeywordsTIGIT / DNAM-1 / CD155 / 免疫チェックポイント分子 / TIL / 乳癌 / 腫瘍免疫 / 癌 / 免疫学
Outline of Final Research Achievements

To analyze the expression of the novel immune checkpoint molecule TIGIT, the paired receptor DNAM-1 and the ligand CD155, immunostaining of TNBC and HER2 positive breast cancer tissue was performed for CD155 / PD-L1 in breast cancer cells and normal ductal epithelial cells, in addition, CD4 / CD8 / CD68 / Poxp3 / TIGIT in TIL. Both TNBC and HER2 positive breast cancer showed more TIL in the tumor part than in the normal part, and more expression of CD8, CD68, and Foxp3. Moreover, the expression of CD155 in breast cancer cells and the expression of TIGIT in TIL were observed. Expression of DNAM-1 in TIL has not been confirmed, and analysis will continue. Furthermore, we succeeded in establishing a soluble CD155 knock-in mouse, and are currently analyzing the interaction of each molecule in carcinogenesis.

Academic Significance and Societal Importance of the Research Achievements

TIGITは免疫チェックポイント分子として新しく見出された分子で、T細胞やNK細胞に発現する抑制性受容体であり、リガンドのCD155を同じくT細胞やNK細胞に発現する活性型受容体DNAM-1と共有する。CD155は膜型のほかに可溶型のアイソフォームを持ち、膜型、可溶型ともTIGIT、DNAM-1と結合することから、可溶型CD155が膜型CD155とTIGITあるいはDNAM-1との相互作用を阻害する可能性などが考えられる。癌組織におけるこれらの分子の発現局在を明らかにするこの研究は、これらの分子の複雑な相互作用を解明する一助になると言える。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (6 results)

All 2020 2019 2018 2017

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (4 results)

  • [Journal Article] High expression of soluble CD155 in estrogen receptor-negative breast cancer2020

    • Author(s)
      4.Iguchi-Manaka A, Okumura G, Ichioka E, Kiyomatsu H, Ikeda T, Bando H, Shibuya A, Shibuya K.
    • Journal Title

      Breast Cancer

      Volume: 27 Issue: 1 Pages: 92

    • DOI

      10.1007/s12282-019-00999-8

    • NAID

      120007127642

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.2020

    • Author(s)
      Okumura G, Iguchi-Manaka A,Murata R,Yamashita-Kanemaru Y, Shibuya A, Shibuya K
    • Journal Title

      Journal of Experimental Medicine

      Volume: 217(4) Issue: 4

    • DOI

      10.1084/jem.20191290

    • NAID

      120007165432

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.2019

    • Author(s)
      Okumura G, Iguchi-Manaka A, Murata R, Yamashita-Kanemaru Y, Shibuya A, Shibuya K
    • Organizer
      第48回日本免疫学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 腫瘍免疫応答における可溶型CD155の役割2018

    • Author(s)
      奥村 元紀
    • Organizer
      第10回血液・疾患免疫療法学会学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] 癌患者血清における可溶型CD155の発現解析2017

    • Author(s)
      井口研子、渋谷彰、渋谷和子
    • Organizer
      第9回血液疾患免疫療法学会学術集会
    • Related Report
      2017 Research-status Report
  • [Presentation] 乳癌における可溶型CD155の発現解析2017

    • Author(s)
      井口研子、渋谷和子、市岡恵美香、都島由希子、池田達彦、坂東裕子、渋谷彰、原尚人
    • Organizer
      第25回日本乳癌学会学術総会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi